Despite SCOTUS, Myriad cashes in on BRCA; J&J on the hunt for deals in Boston;

 @FierceMedDev: St. Jude takes to Japan with MRI-safe pacer. Story | Follow @FierceMedDev

 @DamianFierce: For CROs big and small, you're only as good as your reputation. The view from  DIA 2013. Editor's corner | Follow @DamianFierce

 @MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Report | Follow @MichaelGFierce

> Despite the Supreme Court, Myriad Genetics ($MYGN) is still making money off its BRCA mutation tests, signing a companion diagnostics deal with Tesaro ($TSRO) for a cancer candidate. Article

> Johnson & Johnson ($JNJ) has opened the doors of its Boston Innovation Center, part of a worldwide effort to scout for new deals among early-stage life sciences companies. Story

> In a new study, BioVentrix's Revivent myocardial anchoring system helped heart failure patients sustain 39.6% improvement in heart function after one year. News

> Cepheid ($CPHD) won FDA clearance for its Xpert blood culture test to detect Methicillin-resistant Staphylococcus aureus (MRSA). More

> In new data on Natera's Panorama prenatal screening test, the diagnostic charted an average accuracy of 99.8% in detecting multiple sex chromosome abnormalities. Release

Biotech News

 @FierceBiotech: Big Data guru Atul Butte's NuMedii scores $3.5M VC round for 'digital' drug research. FierceBiotech IT story | Follow @FierceBiotech

 @JohnCFierce: Stanley Family Foundation spearheads a $21M round for Heptares - (GPCRs). News | Follow @JohnCFierce

 @RyanMFierce: J&J's pharma chairman lands 'more deals' in Boston innovation push. Report | Follow @RyanMFierce

> Celgene jumps into blood-cancer race with J&J, adding $818M MorphoSys deal. Report

> Reverse' DNA vaccine bursts into the spotlight with promising Type 1 diabetes data. News

> Genentech eyes 'breakthrough' cancer immunotherapies in pact with U.K. biotech. Story

> U.S. hands out retirement papers to chimps used for research. Article

Pharma News

 @FiercePharma: India suspends Actos on safety concerns. Two other (very old) drugs, too. Report | Follow @FiercePharma

 @EricPFierce: FDA goes from passive to aggressive on compounders. I wonder how long before certain Congressmen complain. More | Follow @EricPFierce

 @CarlyHFierce: Proxy fight heating up at Vivus... First Manhattan announces search for new CEO candidates. Yesterday's story | Follow @CarlyHFierce

> Pfizer, Amgen eye $1B deal for Russian biosimilars developer Biocad. Report

> Novo Nordisk steps away from now-controversial Paula Deen. Article

> Aspen feeds its global appetite with 2nd deal in a week. News

Pharma Manufacturing News

> Aspen, Merck deal includes API plants in U.S., Netherlands. Article

> Roche sets out strict expectations for contractors. Report

> Drugmakers more concerned with quality than price in picking CMOs. Item

> FDA spells out its expectations for crude heparin. More

Vaccines News

> Japan faces vaccine shortage in struggle to control rubella. Report

> ACIP rules on GSK, Novartis and Sanofi vaccines. Story

> Corruption alleged as Indian vaccine shortage continues. Item

> Type 1 diabetes vaccine impresses in early study. News

> Takeda tackling norovirus in bid to grow vaccine biz. Article

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.